Abstract 4232: TLR2 agonist as a novel therapeutic approach to treat pancreatic adenocarcinoma

Abstract 4232: TLR2 agonist as a novel therapeutic approach to treat pancreatic adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with an overall 5-year survival rate of

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2022-06, Vol.82 (12_Supplement), p.4232-4232
Hauptverfasser: Dheeraj, Arpit, Shukla, Chandreshwar, Tailor, Dhanir, Jain, Nayan K., Stefan, Kirsten, Patel, Chintan D., Modi, Rajiv, Khamar, Bakulesh M., Malhotra, Sanjay V.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with an overall 5-year survival rate of
ISSN:1538-7445
1538-7445
DOI:10.1158/1538-7445.AM2022-4232